Skip to content

Author

Katti A. Jessen

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients. In this work, we expl...

Matilde Micillo, Beatrice Pirajno, F. Vallone et al. · 0 citations

Efficacy Is Impacted by

Dual MEK and mTORC1/2 blockade resulted in synergistic antiproliferative effects in cell lines bearing alterations in KRAS/BRAF and PIK3CA/PTEN and a marked proapoptotic response to therapy was observed exclusively in wild-type TP53 colorectal cancer models.

Celina García-García, M. Rivas, Y. Ibrahim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.